Akiko Koizumi1, Tetsuo Sasano2, Wataru Kimura3, Yoshihiro Miyamoto4, Takeshi Aiba4, Taisuke Ishikawa5, Akihiko Nogami6, Seiji Fukamizu7, Harumizu Sakurada7, Yoshihide Takahashi8, Hiroaki Nakamura9, Tomoyuki Ishikura10, Haruhiko Koseki10, Takuro Arimura5, Akinori Kimura5, Kenzo Hirao11, Mitsuaki Isobe12, Wataru Shimizu13, Naoyuki Miura3, Tetsushi Furukawa14. 1. Department of Bio-Informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan. 2. Department of Biofunctional Informatics, Tokyo Medical and Dental University, Tokyo, Japan t_furukawa.bip@mri.tmd.ac.jp sasano.bi@tmd.ac.jp. 3. Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan. 4. Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan. 5. Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan. 6. Division of Cardiology, Yokohama Rosai Hospital, Yokohama, Japan. 7. Department of Cardiology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. 8. Cardiovascular Center, Yokosuka Kyosai Hospital, Yokohama, Japan. 9. Division of Cardiology, Hiratsuka Kyosai Hospital, Hiratsuka, Japan. 10. Department of Genetics Groups, RIKEN Center for Allergy and Immunology, Yokohama, Japan. 11. Department of Cardiovascular Medicine, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan Heart Rhythm Center, Tokyo Medical and Dental University, Tokyo, Japan. 12. Department of Cardiovascular Medicine, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. 13. Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan. 14. Department of Bio-Informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan t_furukawa.bip@mri.tmd.ac.jp sasano.bi@tmd.ac.jp.
Abstract
AIM: Ventricular fibrillation (VF), the main cause of sudden cardiac death (SCD), occurs most frequently in the acute phase of myocardial infarction: a certain fraction of VF, however, develops in an apparently healthy heart, referred as idiopathic VF. The contribution of perturbation in the fast conduction system in the ventricle, the His-Purkinje system, for idiopathic VF has been implicated, but the underlying mechanism remains unknown. Irx3/IRX3 encodes a transcription factor specifically expressed in the His-Purkinje system in the heart. Genetic deletion of Irx3 provides a mouse model of ventricular fast conduction disturbance without anatomical or contraction abnormalities. The aim of this study was to examine the link between perturbed His-Purkinje system and idiopathic VF in Irx3-null mice, and to search for IRX3 genetic defects in idiopathic VF patients in human. METHODS AND RESULTS: Telemetry electrocardiogram recording showed that Irx3-deleted mice developed frequent ventricular tachyarrhythmias mostly at night. Ventricular tachyarrhythmias were enhanced by exercise and sympathetic nerve activation. In human, the sequence analysis of IRX3 exons in 130 probands of idiopathic VF without SCN5A mutations revealed two novel IRX3 mutations, 1262G>C (R421P) and 1453C>A (P485T). Ventricular fibrillation associated with physical activities in both probands with IRX3 mutations. In HL-1 cells and neonatal mouse ventricular myocytes, IRX3 transfection up-regulated SCN5A and connexin-40 mRNA, which was attenuated by IRX3 mutations. CONCLUSION: IRX3 genetic defects and resultant functional perturbation in the His-Purkinje system are novel genetic risk factors of idiopathic VF, and would improve risk stratification and preventive therapy for SCD in otherwise healthy hearts. Published on behalf of the European Society of Cardiology. All rights reserved.
AIM: Ventricular fibrillation (VF), the main cause of sudden cardiac death (SCD), occurs most frequently in the acute phase of myocardial infarction: a certain fraction of VF, however, develops in an apparently healthy heart, referred as idiopathic VF. The contribution of perturbation in the fast conduction system in the ventricle, the His-Purkinje system, for idiopathic VF has been implicated, but the underlying mechanism remains unknown. Irx3/IRX3 encodes a transcription factor specifically expressed in the His-Purkinje system in the heart. Genetic deletion of Irx3 provides a mouse model of ventricular fast conduction disturbance without anatomical or contraction abnormalities. The aim of this study was to examine the link between perturbed His-Purkinje system and idiopathic VF in Irx3-null mice, and to search for IRX3genetic defects in idiopathic VFpatients in human. METHODS AND RESULTS: Telemetry electrocardiogram recording showed that Irx3-deleted mice developed frequent ventricular tachyarrhythmias mostly at night. Ventricular tachyarrhythmias were enhanced by exercise and sympathetic nerve activation. In human, the sequence analysis of IRX3 exons in 130 probands of idiopathic VF without SCN5A mutations revealed two novel IRX3 mutations, 1262G>C (R421P) and 1453C>A (P485T). Ventricular fibrillation associated with physical activities in both probands with IRX3 mutations. In HL-1 cells and neonatal mouse ventricular myocytes, IRX3 transfection up-regulated SCN5A and connexin-40 mRNA, which was attenuated by IRX3 mutations. CONCLUSION:IRX3genetic defects and resultant functional perturbation in the His-Purkinje system are novel genetic risk factors of idiopathic VF, and would improve risk stratification and preventive therapy for SCD in otherwise healthy hearts. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Shan-Shan Zhang; Kyoung-Han Kim; Anna Rosen; James W Smyth; Rui Sakuma; Paul Delgado-Olguín; Mark Davis; Neil C Chi; Vijitha Puviindran; Nathalie Gaborit; Tatyana Sukonnik; John N Wylie; Koroboshka Brand-Arzamendi; Gerrie P Farman; Jieun Kim; Robert A Rose; Phillip A Marsden; Yonghong Zhu; Yu-Qing Zhou; Lucile Miquerol; R Mark Henkelman; Didier Y R Stainier; Robin M Shaw; Chi-chung Hui; Benoit G Bruneau; Peter H Backx Journal: Proc Natl Acad Sci U S A Date: 2011-08-08 Impact factor: 11.205
Authors: K Nademanee; G Veerakul; S Nimmannit; V Chaowakul; K Bhuripanyo; K Likittanasombat; K Tunsanga; S Kuasirikul; P Malasit; S Tansupasawadikul; P Tatsanavivat Journal: Circulation Date: 1997-10-21 Impact factor: 29.690
Authors: Thomas Wichter; Peter Matheja; Lars Eckardt; Peter Kies; Klaus Schäfers; Eric Schulze-Bahr; Wilhelm Haverkamp; Martin Borggrefe; Otmar Schober; Günter Breithardt; Michael Schäfers Journal: Circulation Date: 2002-02-12 Impact factor: 29.690
Authors: Anja Ragvin; Enrico Moro; David Fredman; Pavla Navratilova; Øyvind Drivenes; Pär G Engström; M Eva Alonso; Elisa de la Calle Mustienes; José Luis Gómez Skarmeta; Maria J Tavares; Fernando Casares; Miguel Manzanares; Veronica van Heyningen; Anders Molven; Pål R Njølstad; Francesco Argenton; Boris Lenhard; Thomas S Becker Journal: Proc Natl Acad Sci U S A Date: 2009-12-22 Impact factor: 11.205
Authors: S M J M Straus; G S Bleumink; J P Dieleman; J van der Lei; B H Ch Stricker; M C J M Sturkenboom Journal: J Clin Epidemiol Date: 2004-01 Impact factor: 6.437
Authors: J J Schott; D W Benson; C T Basson; W Pease; G M Silberbach; J P Moak; B J Maron; C E Seidman; J G Seidman Journal: Science Date: 1998-07-03 Impact factor: 47.728
Authors: Kyoung-Han Kim; Anna Rosen; Samer M I Hussein; Vijitha Puviindran; Adam S Korogyi; Carmelina Chiarello; Andras Nagy; Chi-Chung Hui; Peter H Backx Journal: Sci Rep Date: 2016-01-20 Impact factor: 4.379
Authors: Koen T Scholman; Veronique M F Meijborg; Carolina Gálvez-Montón; Elisabeth M Lodder; Bastiaan J Boukens Journal: Front Physiol Date: 2020-05-27 Impact factor: 4.566